Oxford Biomedica PLC 2025 AR2
The report details Oxford Biomedica plc's strategic and financial progress in 2025, highlighting its transition into a pure-play cell and gene therapy CDMO. The company achieved a 31% increase in reported revenues to £168.7 million and reached positive operating EBITDA of £2.3 million. On the environmental front, the group reduced its direct operational emissions by over 6%, achieving a cumulative 39.7% decrease from its 2021 baseline. Additionally, Oxford Biomedica expanded its global footprint with the acquisition of a commercial-scale manufacturing facility in Durham, North Carolina.
Company: Oxford Biomedica PLC
Sector: Professional & technical services
Country: United Kingdom
Year: 2025
Type: AR2
Pages: 196
Back to company
Oxford Biomedica PLC
Annual Report And Accounts
The report details Oxford Biomedica plc's strategic and financial progress in 2025, highlighting its transition into a pure-play cell and gene therapy CDMO. The company achieved a 31% increase in reported revenues to £168.7 million and reached positive operating EBITDA of £2.3 million. On the environmental front, the group reduced its direct operational emissions by over 6%, achieving a cumulative 39.7% decrease from its 2021 baseline. Additionally, Oxford Biomedica expanded its global footprint with the acquisition of a commercial-scale manufacturing facility in Durham, North Carolina.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2025
Reporting Period
Jan 1, 2025 - Dec 31, 2025
Fiscal Year
2025
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Energy Consumption
Renewable Energy
Water Consumption
Total Waste
Women on Board
Women in Management
Net Zero Target
Employees